Discovery of novel PROTACs based on multi-targeted angiogenesis inhibitors.

Anti-angiogenesis has been proved to be an effective strategy for the treatment of tumors. Anti-angiogenic drugs had achieved certain therapeutic effects. However, drug resistance also gradually emerged and limited the application of angiogenesis inhibitors. Proteolysis Targeting Chimeras (PROTACs) are bifunctional molecules capable of degrading proteins through the ubiquitin-proteasome system (UPS). Compared with traditional inhibitors, they displayed advantages of less dosage, lower toxicity and less resistance. In this study, we designed and synthesized a series of novel PROTACs based on our recently reported multi-targeted angiogenesis inhibitor S5. Preliminary biological evaluation of title PROTACs was carried out in various cell lines. The results indicated that these novel bifunctional PROTACs displayed potential in degrading BRAF protein. Their degradation mechanism showed that the degradation of BRAF by PROTAC-1 was dependent on binding to target proteins and E3 ubiquitin ligase. Our findings provided further evidence that these novel PROTACs could be considered in further application in overcome of clinical resistance of traditional angiogenesis inhibitors. Copyright © 2023 Elsevier Ltd. All rights reserved.

Citation

Ru Si, Ping Hai, Yongbiao Zheng, Nanxin Liu, Jin Wang, Qingqing Zhang, Yanchen Li, Xiaoyan Pan, Jie Zhang. Discovery of novel PROTACs based on multi-targeted angiogenesis inhibitors. Bioorganic & medicinal chemistry letters. 2023 May 01;87:129275

Mesh Tags

Substances

PMID: 37030566

search → result